✚ HEALTH & MEDICINE 1 YEAR HORIZON RESOLVES 16 NOV 2027 · in 12mo

The FDA finalizes its guidance on individualized human genome editing products by November 27, 2027.

Draft guidance comments close on November 27, 2026. The milestone is reached when FDA publishes the final regulatory guidance document.

Across 6 frontier models answering independently, the panel leans no: the median is 36%.

They do not agree: Grok puts it at 72% and Claude at 15%, 57 points apart. A spread that wide usually means the question turns on something none of them can see yet.

Nothing is settled until 16 Nov 2027, when the outcome is checked against sources and every number above gets a permanent score.

MODEL BY MODEL

What each one said

  • GrokxAI

    CBER must clear a revised n-of-1 genome-editing guidance within 12 months of the 27 Nov 2026 comment close.

    • FDA typically issues final guidance 9–15 months after docket close; one year sits inside that historical window.
    • The topic is a CBER priority with an existing draft and rare-disease access pressure, lifting it above the median pace.
    • A flood of comments or ethics/off-target inter-agency review would most easily slip the date past 27 Nov 2027.
    x-ai/grok-4.6 · asked 16 Nov 2026
    72%
  • GeminiGoogle

    FDA rarely finalizes complex gene therapy guidance within a single year of public comments closing.

    • FDA's CBER typically requires 18 to 36 months to process novel platform comments and finalize advanced therapy frameworks.
    • The target window gives regulators only 51 weeks post-comment closure, leaving almost no buffer for internal HHS delays.
    • A formal commitment in FDA's annual CBER guidance agenda listing this document by mid-2027 would push odds well above 70%.
    google/gemini-3.8-flash · asked 16 Nov 2026
    42%
  • GPTOpenAI

    FDA must prioritize this draft for finalization within roughly 12 months of the comment deadline.

    • CDER/CBER must review comments, revise the draft, clear it internally, and publish before 16 November 2027.
    • FDA guidance often takes multiple years after comments close; a one-year turnaround is possible but below the usual pace.
    • A public commitment, workshop follow-up, or an expedited review pathway for genome-editing products would materially raise the odds.
    openai/gpt-5.6-terra · asked 16 Nov 2026
    41%
  • QwenAlibaba

    Eleven months from comment close to final guidance is fast for a novel-area FDA document; base rate favors delay.

    • FDA guidance documents in complex novel areas typically take 18–36 months draft-to-final; 11.5 months post-comment-close sits at the aggressive end.
    • The FDA has political and clinical urgency (e.g., individualized base-editing cases) that could compress timelines, but no statutory deadline forces publication by this…
    • A single round of substantial adverse comments or an internal policy shift on somatic vs. germline scope would push this past the window.
    qwen/qwen3.8-max-0902 · asked 16 Nov 2026
    30%
  • DeepSeekDeepSeek

    This turns on whether FDA can turn a comment-heavy draft into a final guidance within roughly twelve months of the comment period closing.

    • FDA's CBER must review comments, reconcile them, and clear the final text through HHS and OMB review before publication.
    • Guidance finalization typically takes 12-24 months after comment close; a one-year turnaround is fast but not unheard of for priority topics.
    • Genome editing is a high-salience area with congressional and public attention, which raises the odds of delay rather than acceleration.
    deepseek/deepseek-v4.1-flash · asked 16 Nov 2026
    22%
  • ClaudeAnthropic

    Whether FDA can finalize guidance within just ~12 months of the comment period closing, which is fast for FDA guidance finalization.

    • FDA draft guidance often takes 2+ years to finalize after comments close due to review backlog and competing priorities.
    • This is a novel, technically complex area (individualized genome editing) likely to draw substantial comments requiring careful review, adding delay.
    • A change in FDA leadership priorities or explicit statutory/political push for rapid finalization would be the main thing that could accelerate this.
    anthropic/claude-sonnet-5 · asked 16 Nov 2026
    15%

6 of 6 models answered · 57 points between the highest and lowest. None was shown the market price.

WHAT DO YOU THINK?
loading…

Question sourced from a news sweep on 16 Nov 2026. Forecast by google/gemini-3.8-flash, anthropic/claude-sonnet-5, openai/gpt-5.6-terra, x-ai/grok-4.6, deepseek/deepseek-v4.1-flash, qwen/qwen3.8-max-0902 via OpenRouter.